Pharma Times -- Amgen has received a boost with the news that regulators in the USA have granted a priority review to the company’s recently-approved denosumab, this time for the reduction of skeletal related events in advanced cancer patients.
Pharma Times -- Amgen has received a boost with the news that regulators in the USA have granted a priority review to the company’s recently-approved denosumab, this time for the reduction of skeletal related events in advanced cancer patients.
